IndianaBiotechnologyHealth CareBiotechnologyHealth Care
Description
BiomEdit has acquired Folium Science's technology platform and pipeline assets, including the poultry feed additive BiomElix® One. This acquisition enhances BiomEdit's capabilities with CRISPR-based microbiome technology. The combined expertise is aimed at improving animal health and production challenges.
Company Information
Company
BiomEdit
Location
Indiana, United States
About
BiomEdit is a pioneering animal health biotechnology company focused on developing innovative solutions for livestock production. Their lead product, BE-101, is the first engineered probiotic biologic designed to combat necrotic enteritis in broiler chickens. BiomEdit aims to enhance poultry health through sustainable, non-antibiotic approaches. The company is advancing toward commercialization with the support of notable investors and strategic partnerships.
Don't miss BiomEdit's next move
Get an email the moment BiomEdit makes an acquisition, hires an exec, or expands, usually minutes after it happens.
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed
Frequently asked
Who acquired Folium Science?
Folium Science was acquired by BiomEdit, based in Indiana. The deal was reported on August 25, 2026. BiomEdit is a pioneering animal health biotechnology company focused on developing innovative solutions for livestock production. BiomEdit is privately held and operates in Biotechnology.
When did BiomEdit acquire Folium Science?
BiomEdit's acquisition of Folium Science was reported on August 25, 2026. BiomEdit has acquired Folium Science's technology platform and pipeline assets, including the poultry feed additive BiomElix® One. This acquisition enhances BiomEdit's capabilities with CRISPR-based microbiome technology. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Folium Science do?
Folium Science has developed precision microbiome technologies including the Guided Biotics® CRISPR-Cas technology. The company focuses on improving animal health through innovative scientific approaches. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.